The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma

2016161 citationsJournal Articlehybrid Open Access

Authors

With longer follow-up, sonidegib demonstrated sustained tumor responses in patients with advanced BCC.

Good health and well-being

Published in: Journal of the American Academy of Dermatology

Volume 75, Issue 1, pp. 113-125.e5

Field-Weighted Citation Impact: 11.86